ClinicalTrials.gg
CompletedNCT01044706Updated Mar 2, 2010Results posted

Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex® 50 mg Tablet in Healthy Subjects Under Fed Conditions

A Phase 1 interventional study of Bicalutamide in Healthy, sponsored by Kremers Urban Development Company. Completed at 1 site in Canada. Open to male participants aged 19 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-03-02.

Sponsored by Kremers Urban Development Company · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
19 Years to 70 Years
Sex
Male
01

Study summary

The objective of this study is to compare the rate and extent of absorption of bicalutamide 50 mg tablet (test) versus Casodex® (reference), administered as 1 x 50 mg tablet under fed conditions.

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalency
03

In context

Lead sponsor

Kremers Urban Development Company is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male, non-smoker, 18 years of age and older;
  • Capable of consent;
  • ≥19.0 and \<30.0 kg/m2.

Exclusion criteria

Exclusion Criteria:

  • illnesses within 4 weeks prior to the administration of the study medication.
  • Clinically significant surgery within 4 weeks prior to the administration of the study medication.
  • Any clinically significant abnormality found during medical screening.
  • Any reason which, in the opinion of the Medical Sub-Investigator, would prevent the subject from participating in the study.
  • Abnormal laboratory tests judged clinically significant.
  • Positive testing for , , or at screening.
  • abnormalities (clinically significant) or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.
  • History of significant alcohol abuse or drug abuse within one year prior to the screening visit.
  • Regular use of alcohol within six months prior to the screening visit (more than fourteen units of alcohol per week [1 Unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]).
  • Use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine, phencyclidine [PCP] and crack) within 1 year prior to the screening visit or positive urine drug screen at screening.
  • History of allergic reactions to heparin, bicalutamide, or other related drugs.
  • Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of inducers: barbiturates, carbamazepine, phenytoin, , omeprazole; examples of inhibitors: antidepressants (SSRI), cimetidine, diltiazem, macrolides, imidazoles, neuroleptics, verapamil, fluoroquinolones, antihistamines) within 30 days prior to administration of the study medication.
  • Use of an drug or participation in an investigational study within 30 days prior to administration of the study medication.
  • Clinically significant history or presence of any clinically significant gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases), unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of the drug.
  • Any clinically significant history or presence of clinically significant neurological, endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric, or metabolic disease.
  • Use of prescription medication within 14 days prior to administration of study medication or over-the-counter products (including natural food supplements, vitamins. garlic as a supplement) within 7 days prior to administration of study medication, except for topical products without systemic absorption.
  • Difficulty to swallow study medication.
  • Use of any tobacco products in the 6 months preceding drug administration.
  • Any food allergy, intolerance, restriction or special diet that, in the opinion of the Medical Sub-Investigator, could contraindicate the subject's participation in this study.
  • A depot injection or an implant of any drug within 3 months prior to administration of study medication.
  • Donation of plasma (500 mL) within 7 days prior to drug administration. Donation or loss of whole blood (excluding the volume of blood that will be drawn during the screening procedures of this study) prior to administration of the study medication as follows:

    • 50 mL to 300 mL of whole blood within 30 days,
    • 301 mL to 500 mL of whole blood within 45 days, or
    • more than 500 mL of whole blood within 56 days prior to drug administration.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Bicalutamide 50 mg Tablet

    Bicalutamide 50 mg Tablet

    Drug: Bicalutamide

  • Active comparator
    Casodex® 50 mg Tablet

    Casodex® 50 mg Tablet

    Drug: Bicalutamide

Interventions

06

What researchers measure

Primary outcomes

  1. AUC0-144 (Area Under the Concentration-time Curve From Time Zero to 144 Hour Post-dose)

    AUC0-144 (area under the concentration-time curve from time zero to 144 hour post-dose)

    Time frame: 144 hour

  2. Cmax (Maximum Observed Concentration of Drug Substance in Plasma)

    maximum observed concentration of drug substance in plasma

    Time frame: 144 hour

07

Results

Posted Mar 1, 2010

Participant flow

healthy subjects recruited in April 2005 by sfbc Anapharm at 2050, Boul. Rene-Levesque Quest, Saint-Foy, Quebec, Canada G1V 2K8

Participant flow — Overall Study
MilestoneBicalutamide 50 mg TabletCasodex® 50 mg Tablet
Started3030
Completed3030
Not completed00

Outcome measures

PrimaryAUC0-144 (Area Under the Concentration-time Curve From Time Zero to 144 Hour Post-dose)

AUC0-144 (area under the concentration-time curve from time zero to 144 hour post-dose)

Time frame:
144 hour
Reported as:
Geometric mean · ng*h/mL
AUC0-144 (Area Under the Concentration-time Curve From Time Zero to 144 Hour Post-dose)
ng*h/mLBicalutamide 50 mg TabletCasodex® 50 mg Tablet
AUC0-144 (Area Under the Concentration-time Curve From Time Zero to 144 Hour Post-dose)114386.56 ± 14285.37105377.55 ± 11989.86
Statistical analysis
  • Bicalutamide 50 mg Tablet vs Casodex® 50 mg Tablet · ANOVA · p = <0.05 (Differences were declared statistically significant at the 5% level (p\<0.05).) · Ratio of t/r geometric mean x 100: 108.46 · 90% CI 102.79 to 114.44Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean for AUCO-144 and Cmax between the test and reference product fall within the interval of 80-125%.
PrimaryCmax (Maximum Observed Concentration of Drug Substance in Plasma)

maximum observed concentration of drug substance in plasma

Time frame:
144 hour
Reported as:
Geometric mean · ng/mL
Cmax (Maximum Observed Concentration of Drug Substance in Plasma)
ng/mLBicalutamide 50 mg TabletCasodex® 50 mg Tablet
Cmax (Maximum Observed Concentration of Drug Substance in Plasma)1253.60 ± 138.021134.86 ± 122.44
Statistical analysis
  • Bicalutamide 50 mg Tablet vs Casodex® 50 mg Tablet · ANOVA · p = <0.05 (Differences were declared statistically significant at the 5% level (p\<0.05).) · Ratio of t/r geometric mean x 100: 110.50 · 95% CI 105.43 to 115.82Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean for AUCO-144 and Cmax between the test and reference product fall within the interval of 80-125%.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bicalutamide 50 mg Tablet——11/30 (36.7%)
Casodex® 50 mg Tablet——18/30 (60%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventBicalutamide 50 mg TabletCasodex® 50 mg Tablet
EcchymosisInjury, poisoning and procedural complications2/302/30
Edema inject siteInjury, poisoning and procedural complications1/302/30
Pain backMusculoskeletal and connective tissue disorders1/302/30
Dry mouthGastrointestinal disorders0/301/30
DyspepsiaGastrointestinal disorders0/301/30
Pain abdomenGastrointestinal disorders1/301/30
AstheniaGeneral disorders1/301/30
PruritusGeneral disorders1/300/30
Hysn inject siteInjury, poisoning and procedural complications0/301/30
Cramp legMusculoskeletal and connective tissue disorders1/300/30

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Bicalutamide 50 mg TabletCasodex® 50 mg TabletTotal
<=18 years000
Between 18 and 65 years292958
>=65 years112
Age Continuous
Age Continuous(years)Bicalutamide 50 mg TabletCasodex® 50 mg TabletTotal
Mean40.13 ± 14.1037.93 ± 14.4139.03 ± 14.18
Sex: Female, Male
Sex: Female, Male(Participants)Bicalutamide 50 mg TabletCasodex® 50 mg TabletTotal
Female000
Male303060
Region of Enrollment
Region of Enrollment(participants)Bicalutamide 50 mg TabletCasodex® 50 mg TabletTotal
Canada303060
08

Study locations

1 site
  • SFBC Anapharm
    sainte-Foy, Quebec G1V 2K8, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2005, a primary completion of Jul 2005 and a completion of Jul 2005. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2010, 4 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2010
First posted
Jan 8, 2010
Start
May 2005
Primary completionActual
Jul 2005
CompletionActual
Jul 2005
Results first posted
Mar 1, 2010
Last update
Mar 2, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01044706
Lead sponsor
Kremers Urban Development Company
First posted
Jan 8, 2010
Start date
May 2005
Primary completion
Jul 2005
Completion
Jul 2005
Results posted
Mar 1, 2010
Last update
Mar 2, 2010

Study contacts

Benoit Girard, M.D.
principal investigator · SFBC Anapharm

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bicalutamide

Start the discussion